Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 77, Issue , 2013, Pages 1-8

  Lüthi, Guillaume ^a   Blangy, Valeria ^a   Eap, Chin B ^a,b   Ansermot, Nicolas ^a  

^a Hopital de Cery   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Buprenorphine; Human plasma; Norbuprenorphine; Protein precipitation; Quantification; UHPLC MS MS

Indexed keywords

ACETONITRILE; AMMONIUM FORMATE; BUPRENORPHINE; NORBUPRENORPHINE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ISOLATION; ELECTROSPRAY; FLOW RATE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIMIT OF QUANTITATION; MEASUREMENT REPEATABILITY; OBSERVATIONAL STUDY; PH; PRACTICE GUIDELINE; PRECIPITATION; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; STANDARD; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

BUPRENORPHINE; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 84873854041     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.12.023     Document Type: Article

References (34)

1. United Nations Office on Drugs and Crime, World Drug Report 2011, (last access July 2012). http://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf.
2. European Monitoring Centre for Drugs and Drug Addiction, Annual Report 2011, (last access July 2012). http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf.
3. Ducharme S., Fraser R., Gill K. Update on the clinical use of buprenorphine: in opioid-related disorders. Can. Fam. Physician 2012, 58:37-41.
4. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001, 154:230-242.
5. Chawarski M.C., Moody D.E., Pakes J., O'Connor P.G., Schottenfeld R.S. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J. Subst. Abuse Treat. 2005, 29:307-312.
6. Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada N., Ishizaki T., Kuroiwa Y. Human buprenorphine n-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 1998, 26:818-821.
7. Huang P., Kehner G.B., Cowan A., Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 2001, 297:688-695.
8. Coffman B.L., King C.D., Rios G.R., Tephly T.R. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 1998, 26:73-77.
9. Brown S.M., Campbell S.D., Crafford A., Regina K.J., Holtzman M.J., Kharasch E.D. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J. Pharmacol. Exp. Ther. 2012, 343:53-61.
10. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004, 75:13-33.
11. Klein K., Thomas M., Winter S., Nussler A.K., Niemi M., Schwab M., Zanger U.M. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 2012, 91:1044-1052.
12. Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., Fric M., Gerlach M., Greiner C., Grunder G., Haen E., Havemann-Reinecke U., Jaquenoud Sirot E., Kirchherr H., Laux G., Lutz U.C., Messer T., Muller M.J., Pfuhlmann B., Rambeck B., Riederer P., Schoppek B., Stingl J., Uhr M., Ulrich S., Waschgler R., Zernig G. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011, 44:195-235.
13. LaForge K.S., Yuferov V., Kreek M.J. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. 2000, 410:249-268.
14. Lawford B.R., Young R.M., Noble E.P., Sargent J., Rowell J., Shadforth S., Zhang X., Ritchie T. The D 2 dopamine receptor A 1 allele and opioid dependence: association with heroin use and response to methadone treatment. Am. J. Med. Genet. 2000, 96B:592-598.
15. Elkader A., Sproule B. Buprenorphine - clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 2005, 44:661-680.
16. Rodriguez-Rosas M.E., Lofwall M.R., Strain E.C., Siluk D., Wainer I.W. Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry. J. Chromatogr. B 2007, 850:538-543.
17. Polettini A., Huestis M.A. Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2001, 754:447-459.
18. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., Foltz R.L. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 2002, 306:31-39.
19. Ceccato A., Klinkenberg R., Hubert P., Streel B. Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J. Pharm. Biomed. Anal. 2003, 32:619-631.
20. Selden T., Roman M., Druid H., Kronstrand R. LC-MS-MS analysis of buprenorphine and norbuprenorphine in whole blood from suspected drug users. Forensic Sci. Int. 2011, 209:113-119.
21. Oiestad E.L., Johansen U., Oiestad A.M., Christophersen A.S. Drug screening of whole blood by ultra-performance liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2011, 35:280-293.
22. Verplaetse R., Tytgat J. Development and validation of a sensitive UPLC-MS/MS method for the analysis of narcotic analgesics in urine and whole blood in forensic context. Forensic Sci. Int. 2011, 215:136-145.
23. Guo Q., Du Z. Development of a rapid and simultaneous detection method for buprenorphine, norbuprenorphine and naloxone in human plasma using ultra-high performance liquid chromatography-tandem mass spectrometer with solid-phase extraction. Chin. J. Chem. 2011, 29:1922-1926.
24. Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation 2001, (last access July 2012). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
25. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays - Workshop/Conference Report. AAPS J. 2007, 9:E30-E42.
26. European Medicines Agency, Guideline on Bioanalytical Method Validation 2011, (last access July 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
27. Hubert P., Nguyen-Huu J.J., Boulanger B., Chapuizet E., Chiap P., Cohen N., Compagnon P.A., Dewe W., Feinberg M., Lallier M., Laurentie M., Mercier N., Muzard G., Nivet C., Valat L. Validation of quantitative analytical procedure. Harmonization of approaches. STP Pharma. Pract. 2003, 13:101-138.
28. Rozet E., Ceccato A., Hubert C., Ziemons E., Oprean R., Rudaz S., Boulanger B., Hubert P. Analysis of recent pharmaceutical regulatory documents on analytical method validation. J. Chromatogr. A 2007, 1158:111-125.
29. Bonfiglio R., King R.C., Olah T.V., Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13:1175-1185.
30. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
31. Chapuzet E., Mercier N., Bervoas-Martin S., Boulanger B., Chevalier P., Chiap P., Grandjean D., Hubert P., Lagorce P., Lallier M., Laparra M.C., Laurentie M., Nivet J.C. Méthodes chromatographiques de dosage dans les milieux biologiques: stratégie de validation - rapport d'une commission SFSTP. STP Pharma. Pract. 1997, 7:169-194.
32. Noetzli M., Ansermot N., Dobrinas M., Eap C.B. Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS. J. Pharm. Biomed. Anal. 2012, 64-65(64):16-20.
33. Polson C., Sarkar P., Incledon B., Raguvaran V., Grant R. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2003, 785:263-275.
34. Favretto D., Frison G., Vogliardi S., Ferrara S.D. Potentials of ion trap collisional spectrometry for liquid chromatography/electrospray ionization tandem mass spectrometry determination of buprenorphine and nor-buprenorphine in urine, blood and hair samples. Rapid Commun. Mass Spectrom. 2006, 20:1257-1265.